The molecular story of COVID-19; NAD⁺ depletion addresses all questions in this infection

Shirin Kouhpayeh¹†, Laleh Shariati²,³†, Maryam Boshtam⁴, Ilnaz Rahimmanesh⁵, Mina Mirian⁶, Mehrdad Zeinalian⁵, Azhar Salari-jazi⁷, Negar Khanahmad⁸, Mohammad Sadegh Damavandi⁷, Parisa Sadeghi⁷, Hossein Khanahmad*†

1. Department of Immunology, Erythron Genetics and Pathobiology Laboratory, Isfahan, Iran
2. Department of Biomaterials, Nanotechnology and Tissue Engineering, School of Advanced Technologies in Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
3. Applied physiology research center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, I.R. Iran.
4. Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
5. Department of genetics and molecular biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
6. Isfahan Pharmaceutical science research center, School of Pharmacy and Pharmaceutical Science, Isfahan University of Medical Sciences, Isfahan, Iran.
7. Department of Microbiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
8. School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

†These authors contribute equally to this work

*Corresponding author: Dr. Hossein Khanahmad

Isfahan University of Medical Sciences, School of Medicine, Department of Genetics and Molecular Biology, Isfahan, Iran.

Phone: +98-313-7929144

Fax number: +98-313-6688597

H_khanahmad@med.mui.ac.ir
The contributors’ statement:

The authors, Laleh shariati, Shirin Kouhpayeh and Hossein Khanahmad contributed in study design and data interpretation. Hossein Khanahmad, Maryam Boshtam, Ilnaz Rahimmanesh, Laleh Shariati, Mina Mirian and Mehrdad Zeinalian contributed in literature search and data collection. Azhar Salari-jazi, Parisa Sadeghi, Negar Khanahmad, Mohammad Sadegh Damavandi contributed in data analysis. Ilnaz Rahimmanesh contributed in figure provided.

The authors, Hossein Khanahmad, Maryam Boshtam, Shirin Kouhpayeh and Laleh Shariati contributed in drafting the paper.
Abstract
The emerging new Coronaviridae member, nCoV 19, outbreak announced a pandemic by WHO with an increasing morbidity and mortality rate worldwide. nCoV 19 known as the third highly pathogen coronavirus in human population after the severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV), the nCoV 19.

The renin–angiotensin (RAS) signaling pathway, oxidative stress and cell death, cytokines storm and endothelial dysfunction are four major pathways involved in the pathogenesis of nCoV 19. Acute respiratory distress syndrome (ARDS) generally develops with a massive oxidative/nitrosative stress following virus entry and RAS activation. The DNA damage subsequent to oxidative burst activates poly-ADP ribose polymerase-1 (PARP-1), viral macrodomain (NSP3) poly (ADP-ribose) glycohydrolase (PARG) and transient receptor potential channel, melastatin 2 (TRPM2) in a sequential manner ultimately leading to apoptosis and necrosis due to NAD and ATP depletion. Regarding the molecular mechanisms involved in nCoV 19 pathogenesis, angiotensin II receptor blockers and/or PARP, PARG and TRPM2 blockers could be engaged as therapeutic candidates for inhibition of RAS and quenching oxidative stress, respectively. In this review, the molecular aspects of nCoV 19 pathogenesis would be studied precisely and possible therapeutic targets would be proposed. It is recommended to evaluate the proposed drugs and supplements via registered clinical trials along with conventional guideline-based multi-drug regimen.

Key Words: COVID-19; nCoV 19; Oxidative stress; PARP; PARG; TRPM2
1. Introduction

The new viral pneumonia caused by the 2019 novel coronavirus (nCoV19) is a highly contagious disease, and the ongoing outbreak has been declared by WHO as a global public health threat (1, 2). The nCoV 19 known as the third highly pathogen coronavirus in human population after the severe acute respiratory syndrome coronavirus (SARS-CoV-2002) and the Middle East respiratory syndrome coronavirus (MERS-CoV-2012) in the 21st century (3). The nCoV19 categorized in Coronaviridae family along with about 40 species as single-stranded positive-sense RNA viruses. The nCoV 19 classified in β-coronaviruses cluster based on sequence analysis study together with SARS-CoV and MERS-CoV (4) with more than 82% similarity to those of SARS-CoV. Coronaviruses known as human infectious agents in the last few decades while primarily identified as a source for enzootic infections in birds and mammals (5). At present, the incidence of coronavirus disease 19 (COVID-19) have been found in more than 100 countries around the world (6). According to the latest data, the number of confirmed cases in the world reached 244919, up to the March 20, 2020, of which 10031 deaths, were reported.

Considering the lack of any registered therapeutic or preventive strategy for COVID-19, there is an urgent need to find an alternative solution for prevention and control of global distribution of virus. Therefore, the molecular mechanisms involved in nCoV 19 pathogenesis or recruited by the virus would be studied precisely in this review and possible therapeutic targets and a number of approved drugs would be introduced.
2. Pathogenesis and Therapeutic Targets

2.1 Clinical manifestations- Fever, nonproductive cough, nasal congestion and fatigue as the clinical characteristics of COVID-19 start after less than a week of infection. About 75% of patients show severe disease as seen by computed tomography scan on admission (1). On the day 10 to 20 of the symptomatic infection, pneumonia occurs which is associated with reduced oxygen saturation, blood gas deviations and sharp changes of chest X-ray as prominent signs of COVID-19. Lymphopenia and elevation of inflammatory markers including C-reactive protein and pro-inflammatory cytokines considered as diagnostic clinical laboratory manifestation (1, 7).

The exact mechanism of nCoV-19 pathogenesis is still unknown, although Lu et al revealed nCoV 19 is genetically similar to SARS-CoV-1 and MERS-CoV, 79% and 50%, respectively. In addition, homology modelling showed the structure of receptor binding domain in nCoV 19 is similar to SARS-CoV-1. This evidence suggests nCoV 19 pathogenesis resembles SARS-CoV-1 infection (8, 9), thus too much information can be gained based on this similarity for a better understanding of COVID-19.

2.2 Coronavirus life cycle- Coronaviruses are believed to enter the host cells through interaction of spike protein (S protein) and angiotensin-converting enzyme 2 (ACE2) receptor, also known as COVID-19 specific cellular receptor (10, 11). The one step proteolytic cleavage mediates by host cell protease in certain SARS-CoV S protein residue (position S2’), facilitates direct membrane fusion between viral and plasma membrane (12). Previous studies have shown SARS-CoV cell entry also occurs through ACE2 receptor as the preferred receptor (13, 14).
While MERS-CoV has developed a strange two-step furin-mediated membrane fusion (15). Upon entry into the host cells, the viral RNA genome is translated into two polyproteins and structural proteins in the cytoplasm, which helps the assembly of virus progeny (16). Ultimately, following assembly of emerging envelope glycoproteins and the genomic RNA, budding occurs in the endoplasmic reticulum-Golgi intermediate compartment (7).

2.3 The renin–angiotensin (RAS) signaling pathway- Particularly, ACE2 is an ACE homolog belongs to ACE family of dipeptidyl carboxydipeptidases which obviously counter balances the ACE physiological function. ACE is responsible for production of angiotensin II by cleavage of angiotensin I which subsequently binds to angiotensin Type-1 Receptor (AT1R) and alters blood pressure, body fluids and electrolyte homoeostasis. In contrast, ACE2 inactivates angiotensin II by catalyzes the elimination of the C-terminal phenylalanine residue in order to generate angiotensin 1–7. This peptide potentially exerts vasodilatory action and negatively regulates renin–angiotensin system. Thus, in nCoV 19 pathogenesis, RAS acts as a double edge sword, as a receptor for the virus entry and a negative regulator for severe symptoms of infection and lung injury (17, 18).

Earlier studies in SARS-CoV pathogenesis proved the binding of the SARS-CoV protein S to ACE2 receptor, is associated with ACE2 downregulation, excessive production of angiotensin by ACE and less vasodilatory function of heptapeptide angiotensin 1–7. This process leads to excessive production of pro-atrophic, pro-fibrotic, pro inflammatory and
pro-oxidant agents thus exacerbates lung injury and enhances pulmonary vascular permeability (Fig. 1) (19).

The lungs provide a massive surface of about 100 m^2 for viral entry. On the other hand, existence of alveolar epithelial type II cells (AECII) creates an appropriate viral reservoir in human alveolar epithelial cells. Moreover, multiple viral process-associated genes in AECII, could simplify virus progeny release in these cells (19, 20).

2.4 Oxidative stress and cell death- Oxidative stress is triggered by the imbalance between the oxygen reactive species (ROS) production and clearance. ROS as metabolic by-products including hydrogen peroxide (H2O2), Superoxide radicals (O2 •− ), singlet oxygen (1 O2), hydroxyl radicals (•OH) and peroxynitrite anion (ONOO−) are produced using biological systems (21). Both viral infections and RAS activation produce ROS in a reproductive manner leading to oxidative burst. Increased ROS levels lead to destructive effects on cellular macromolecules such as lipids, proteins and especially nucleic acids (22).

The exogenous (environmental) and endogenous (intracellular) sources of free radicals constantly cause DNA damage. Another source of free radical generation which is generally underestimated is the exposure to viral infections (23).

Oxidative stress-mediated DNA damage is repaired primarily via the base excision repair (BER) pathway which appears to be the simplest pathway among the three excision repair pathways (23).

Normally, poly-ADP ribose polymerase-1 (PARP-1), a DNA base repair enzyme, activated by DNA breaks and contributes to BER pathway for maintenance of genome stability.
Upon activation, PARP-1 rapidly uses the substrate NAD$^+$ to transfer poly ADP-ribose (PAR) to itself, nuclear acceptor proteins and damaged DNA (24).

PARP-1 has ADP-ribosyl transferase (monomer or polymer) activity and functions as an antiviral agent through ADP-ribosylation of viral genome (RNA or DNA) and inhibition of viral transcripts translation. However, several viral families, including Togaviridae, Hepeviridae and Coronaviridae encode for a macrodomain protein with poly (ADP-ribose) glycohydrolase (PARG) activity which hydrolyzes ADP-ribose units from proteins and nucleic acids to facilitate optimal replication and virulence(25).

Excessive activation of PARP occurs to compensate ADP-ribose hydrolyzation of PARG which is associated with catalytic consumption of NAD$^+$ followed by ATP reduction leading to depletion of energy and cell death (26).

On the other hand, PARP and subsequent PARG activation following the deep DNA damage generates large amounts of free ADP-Ribose units which bind to transient receptor potential channel, melastatin 2 (TRPM2) through a functional ADP-Ribose hydrolase domain in its C terminus (27). Intracellular calcium concentration and ADP-ribose known as activators of TRPM2 (27, 28). Lysosomal and plasma membrane TRPM2, cause Ca$^{2+}$ influx across the plasma membrane and release of lysosomal Ca$^{2+}$, providing high concentration of Ca$^{2+}$ in the cytosol. The overload of cytosolic Ca$^{2+}$ initiates apoptosis and probably necrosis (29, 30). This might be the possible explanation of severe lung injury in COVID-19 patients. Moreover, TRPM2 ability to response to oxidative stress made it a promising target for development of new small molecule and therapeutic approach such as aptamer (31) and gene editing tools (32, 33)(Fig 1).
2.5 Cytokines storm- A well-synchronized immune response is essential for control and eradication of nCoV and other viral infections. However, maladjusted and uncontrolled immune responses to viral progeny release may cause cytopathic effect during nCoV infections. The host innate immune system detects virus and a rapid immune response initiates after virus-cell interaction (34).

The antigen-presenting cells (APCs), including macrophages present nCoV antigens to T cells subsequent to nCoV 19 entrance into the host cells. This process leads to T cell activation and production of cytokines in various T cell subsets i.e. Th17, followed by a massive release of cytokines due to positive feedback loop between cytokines and immune cells. On the other hand, during nCoV 19 replication, virus genomic dsRNA activates interferon regulatory factors (IRFs) and TLR-3-induced NF-κB pathway which culminates in production of type I IFNs and proinflammatory cytokines in large quantities (35).

Dysregulation of immune responses following hyper-inflammation and cytokine storm, may lead to multiple organ failure, pulmonary tissue damage, and reduced lung capacity which is well-known in patients with COVID-19 infection (34, 36).

Present data in COVID-19 infected patients showed a significantly increased level of plasma pro-inflammatory cytokines including MCP1, MIP1α, MIP1β, IL1-β, IL1RA, IL7, IL8, IL9, IL10, IP10, PDGFB basic FGF2, GCSF, GMCSF, IFNγ, TNFα, and VEGFA (37).

In conclusion, viral infection initiates a detrimental cycle of oxidative stress-mediated functions including PARP and PARG activity, ADP ribose increase, TRPM2 activity, apoptosis and/or necrosis (parthanatos) (38) and inflammatory and vasodilator agents
release. Together, all these mechanisms result in endothelial dysfunction and extravasation of immune cells in alveolar space and finally a ground glass pattern in chest X ray. The trapped immune cells release large amounts of cytokines which leads to systemic inflammatory response syndrome (SIRS), a figure usually seen in septic shock and other cause of acute respiratory distress syndrome (ARDS) like paraquat (1,10-dimethyl-4,40-bipyridinium dichloride; PQ) poisoning (39)(Fig 1).

2.6 Endothelial dysfunction- The earliest and one of the most important indicators of endothelial dysfunction is chronic reduction of nitric oxide (NO) synthesis, release or activity and/or increased NO degradation by reactive oxygen species (ROS) (40). The reduced NO bioavailability results in proliferative, pro-oxidant, pro-inflammatory, and pro-thrombotic responses. Thus various pathological disorders affect endothelial function through changing the molecular mechanisms involved in regulation of NO bioavailability (41).

The appropriate environment for coronavirus life cycle is an oxygen-depleted condition. In the hypoxic situation, ROS generation, and HIF-1a activation occurs sequentially, which (42), consequently induces the expression of furin enzyme (43) and ultimately viral activation.

In the hypoxic milieu, nitric oxide release enhanced by function of nitric oxide synthases (NOSs) using L-arginine amino acid for maintenance of nitroso/redox balance (41, 44). The NOSs function is dependent to adequate amounts of tetrahydrobiopterin (BH4) in its
active reduced form (45, 46). In the oxidative stress state, extra free radicals interfere with redox homeostasis and adequate BH4 production (47). It could be concluded the altered redox homeostasis leads to reduced levels of NO in COVID-19 patients with oxidative burst and RAS activation.

Decreased levels of NO, shows various properties attributed to inflammation and cardiovascular events concomitant with endothelial dysfunction. Low levels of NO is capable of inducing vascular smooth muscle cells (VSMCs) proliferation (48), LDL oxidation (49), and vascular cell adhesion molecule-1 (50) and Monocyte chemoattractant protein 1 (MCP1) expression (51) through inhibition of NF-kappa B signaling pathway. Moreover, decreased NO following oxidative burst, stimulates matrix metalloproteinases-2 and 9 (52, 53) as well as induction of pro-inflammatory cytokines and chemokines expression (54). Platelet aggregation (55), leukocyte adhesion (56) and thrombolysis stimulation (54) are also considered as other characteristics of reduced NO level contributing in endothelial dysfunction.

Although, decreased NO production is prominent in COVID-19 patients, a few clinical manifestation of patients described due to slightly increased level of NO. NO is considered an important factor in vascular homeostasis (49) due to the role of NO in inhibition of contractile machinery and vasodilation. In this process, NO which was produced by endothelial cells, spreads into VSMCs and generates cyclic guanosine-3,5-monophosphate (cGMP). Subsequently, cGMP-dependent protein kinase is activated and removal of cytosolic Ca2+ occurs which is associated with inhibition of the contractile machinery and ultimately, vasodilation (54, 57, 58). On the other hand, NO release in peripheral vessels
may worsen hemodynamic homeostasis and decrease the blood pressure and organ perfusion.

Another mechanism for NO release from endothelial cells, might be due to shear stress and ischemia (49, 54), which enhanced by acetylcholine, bradykinin and serotonin (54)(Fig 1).

3. Possible therapeutic options for COVID-19

Regarding the molecular mechanism involved in nCoV 19 pathogenesis, several proteins including ACE2, ATR1, NADPH oxidase, PARP, PARG Macrdomain or NSP3, and TRPM2 could be considered for target therapy using synthetic drug or natural compound candidates which are further discussed in following sections.

3.1 Vitamin D- Recently, variety of vitamins have been suggested for treatment or improvement of nCoV 19 infection symptoms. Vitamin D showed significant effects through binding to the ACE2 receptor which mediates acute lung injury in host cells during nCoV 19 infection (59, 60). The high expression of ACE2 receptor on the surface of human alveolar epithelial cells significantly facilitates coronavirus internalization and infection (19). Based on experimental studies, administration of vitamin D agonist, calcitriol, exerts protective effects on lung injury through modulating components of RAS such as ACE I and ACE II, renin and Ang II (59). Thus, vitamin D deficiency may directly promote hypertension through impacts on members of RAS (61).

Another protective function which has been proposed for vitamin D, is immunomodulation through suppressing pro-inflammatory cytokines. Hence, vitamin D supplements may ameliorate the cytokine storm following nCoV 19 infection. (62). In vitamin D deficiency, the ACE II receptor binding sites are exposed on the cell surface which could
further enhances the viral entry into the host cells. Thereby, it seems vitamin D is considered as a critical player in capability of nCoV 19 infection. Furthermore, although vitamin D is considered as a known PARP inhibitor (63), vitamin D provides increased amounts of extracellular calcium which functions as a potent activator of TRPM2 (97). Thus, administration of vitamin D in COVID-19 patients is still controversial.

3.2 **Thalidomide**- Thalidomide previously known as an effective NSAID, while the application of thalidomide was banned due to its teratogenic effects. On the other hand, various antiviral properties including inhibition of PARP, anti TNF and NADPH oxidase inhibition effects have been assigned to thalidomide (99).

3.3 **Trehalose**- Trehalose is a non-reducing disaccharide and generally applied as a stabilizer in drug formulation. Trehalose inhibits PARP1 and PARP2, thus could be used as a filler in vitamin B3 or NAD tablets and further prescribed for nCoV 19 infected patients through a registered clinical trial (64).

3.4 **N-acetylcysteine (NAC)**- NAC has been used for treatment of poisoning with toxin and some drugs due to its PARP inhibitory and antioxidant activity, thus might be a suitable candidate in treatment and control of nCoV 19 infection symptoms (65).

3.5 **Tannins**- Tannins are water-soluble polyphenolic compounds which have been known as health-promotor components (66). Several studies have reported the antiradical activities of tannins (66). Moreover, the anti-inflammatory effects of tannins were also reported in previous studies (67, 68). Based on the molecular mechanisms recruited by nCoV 19 during pathogenesis in human body, COVID-19 is considered as an inflammatory disorder, thus tannins as the magic antioxidants can reduce the disease morbidity and mortality due to their role in redox homeostasis maintenance. In addition, inhibitory effect of tannins on
PARG enzyme was reported previously (38). An in silico study showed the tannins also bind to ADP ribose specific binding site in TRPM2 and supposed to be the TRPM2 inhibitor but this should be more evaluated by further experiments. Gallotannin as hydrolysable tannins showed to inhibit cytokine expression (38).

3.6 **Flufenamic Acid and clotrimazole**- These drugs inhibit TRPM2 in a non-selective manner and are capable to inhibit or activate other ion channels as well (69). Flufenamic acid activates AMP-activated protein kinase (AMPKα-P) and suppresses NFκB expression and ultimately shows anti-inflammatory function (70).

Another small molecule against PARP such as olaparib or other paribs might be appropriate candidate for COVID19 treatment (69).

3.7 **NAD+ and niacin**- In the depicted molecular pathology pathway of COVID-19, almost all procedures lead to or originate from NAD+ depletion. NAD+ depletion mediated by uncontrolled PARP activity leads to decreased sirtuin 1 (SIRT1) activity indirectly. SIRT1 deacetylates nuclear proteins using NAD+ to regulate the expression of genes including tumor suppressors, cytokines and proto-oncogenes and ultimately modulate inflammation, cell survival and apoptosis mechanisms (71). NAD and ATP are prerequisite for each other and consumption of NAD in large amounts decreases ATP levels leading to impairment of all activities and integrity of the cell. In COVID-19-mediated ARDS, aldosterone level is decreased and patients are hypovolemic in spite of RAS activation. It seems that aldosterone synthesis is silenced somewhere in CNS or adrenal gland. The logical interpretation is serotonin shortage which is an important molecule and has several roles in biology including stimulation of aldosterone secretion (72). In COVID-19 patients, the resources of tryptophan-as the raw material for serotonin and NAD synthesis- spend and
in ARDS course of the disease serotonin is decreased and hypoaldostronism causes hyponatremia and hypovolemia. Fatigue and various degrees of mood disorders are the consequences of NAD, ATP and serotonin reduction, which could be addressed by concomitant prescription of NAD, Niacin (Vitamin B3) and/or its precursor L tryptophan with a PARP or PARG inhibitor. It is possible that administration of NAD alone, along with high activity of PARP and PARG, worsen the clinical manifestation.

3.8 **Losartan**- Based on previous experimental studies, losartan, the angiotensin II receptor antagonist, reduces the synthesis of TGF-1β and PARP. Hence, losartan seems to be able to prevent or control chronic fibrotic diseases such as cardiac hypertrophy and asthma in addition to hypertension (73-76). In an animal study, losartan therapy improved paraquat-induced pulmonary fibrosis. It seems losartan acts through inhibition of TGF-1β mRNA expression and synthesis of collagen. This could provide enough evidences for application of losartan for the prevention of pulmonary fibrosis (39).

Moreover, Apart from direct anti-hypertensive effects of losartan, it provides significant reduction of platelet aggregation by ristocetin and reduced hematocrit with hemoglobin, following administration in newly diagnosed hypertensive patients which is suggestive for applying losartan for thrombosis and atherosclerosis as well (77).

Another mechanism of action for losartan considered to be the immunomodulatory function and significantly regulating IFN-γ, IL-6, IL-17F and IL-22 cytokines in PBMCs of rheumatoid arthritis patients (78).

Another animal study provided evidence of losartan significant effects on sever acute lung injury (ALI) and ARDS (ALI/ARDS), which might be due to inhibition of NF-kappaB and
MAPK signaling pathways (79). Activation of RAS system ignites a strong oxidative stress as the key pathogenic mechanism in COVID19.

An earlier hypothesis illustrated that losartan as an angiotensin receptor 1 (AT1R) blocker in RAS pathway could be useful for patients infected by COVID-19 who experience pneumonia (80). Losartan and olmesartan, AT1R antagonists, commonly applied for treatment of hypertensive patients which have overexpression of ACE2, major receptor for virus entry in both rat and human (81, 82).

Although, half of COVID-19 patients experience hypotention during their hospitalization but based on premature estimation, percentage of SARS patients of the currently ongoing epidemic can be properly cured with AT1R blockers without risking exacerbated hypotension (20). These candidates of SARS-CoV-2 therapeutics suggested for treating patients prior to the development of acute respiratory syndrome but this hypothesis certainly should be approved with experimental and clinical investigation (20). COVID-19 infection induces some degree of fibrosis in lung which correlates with the severity of the disease, thus, losartan may protect the involved organs from fibrosis and decrease morbidity of disease.

Based on the existing evidences, TRPM2 could be an appropriate therapeutic target in nCoV 19 life cycle. There are several small molecules inhibiting TRPM2, including Flufenamic acid (FFA) (83, 84), 2-(3-methylphenyl) aminobenzoic acid (3-MFA) (83), N-(pamylcinnamoyl) anthranilic acid (ACA) (85), econazole, clotrimazole (86) and 2-aminoethoxydiphenyl borate (2-APB) (87, 88), while, none of them are TRPM2 channel specific (89). Furthermore, some nucleoside analogues like adenosine monophosphate (AMP) and 8-bromoadenosine 5′-diphosphoribose (8-Br-ADPR) have also been mentioned
as TRPM2 inhibitors (27, 90). Two novel TRPM2 channel inhibitors have been synthesized (69) by modification of ADPR analogues including 8-phenyl-2′-deoxy-ADPR which specifically inhibits TRPM2 without interfering Ca2+ release induced by cADPR, NAADP or IP3 (91).

3.9 Monoclonal Antibodies and recombinant proteins

Neutralizing antibodies against nCoV 19 surface antigens prevent virus entry of which, S protein considered as a good candidate. These monoclonal neutralizing antibodies provide a passive immunity in the time of exposure like palvizumab as a putative example that has been applied for prevention of RSV infection (92). Anti-inflammatory antibodies like anti IL6 receptor (Tocilizumab) and anti ITGA4 (Natalizumab) may inhibit inflammation and cellular extravasion (101, 102). Another proposed strategy is administration of soluble ACE2 receptor to scavenge the virus. The similar procedure has been applied in HIV infection using soluble CD4 in HIV infection.

4. Conclusion

As a clinical manifestation, ARDS occurs during viral infection like nCoV 19, septic shock, poisoning and chemical warfare agents. The prognosis of ARDS is poor and there is no specific treatment for it. ARDS generally begins with a massive oxidative/nitrosative stress and the subsequent DNA damage activates PARP, endogenous PARG and TRMP2 activity which ends in apoptosis, necrosis and parthanatosis. nCoV 19 expresses NSP3 as a potent extraneous PARG and likely activates RAS that provides fuel for oxidative stress in this circuit. This detrimental cycle consumes NAD and decreases antioxidant capacity thus enhances
inflammation and cytokin release. NAD is consumed in large scale by PARP and its depletion inhibits the activity of other protective protein like SIRT1 and CD38. Expression of NFkB and cytokines and blood and immune cell defects are the consequences of SIRT1 and CD38 inhibition respectively. L tryptophan is the common raw material for NAD and serotonin synthesis and NAD depletion leads to reduction of serotonin indirectly. Since serotonin is important for aldosterone secretion and has several positive cardiovascular effects, COVID-19 patients suffering hypovolemia and hypoaldosteronism due to serotonin depletion in spite of RAS overactivation that usually ends to hypervolemia and hypertension. According to above vision of nCoV 19 molecular pathology, there are several therapeutic candidates engaged for COVID-19 treatment. Inhibition of RAS activation by Angiotensin II receptor blockers like losartan with known PARP inhibitory effect could quench oxidative stress and interrupt this circuit. Moreover, renin inhibitors like aliskiren which suppresses RAS could also be recommended for COVID-19 treatment. PARP inhibitors like trehalose, olaparib, losartan, vitamin D and NAC are another therapeutic options in nCoV 19 infection. Apocynin is an NADPH oxidase inhibitor and could cut the detrimental circuit. PARG and TRPM2 antagonist including tannins, fluenamic acid and clotrimazole proposed for TRPM2 inhibition as well. In addition to suggested drugs, taking NAD or Vitamin B3 plus L-tryptophan could replenish NAD and serotonin and recover the body toward hemostasis. It should be considered that using NAD alone could worsen the COVID-19 symptoms, thus PARP, PARG and TRPM2 inhibitors might be prescribed in the first step. Vitamin D and losartan appeared to overexpress ACE2 and might increase viral entrance. Vitamin D also increases extracellular calcium and could activate TRPM2. However, the level of AgII in COVID-19 is high and upregulation of ACE2 following losartan intake runs the protective brunch of RAS pathway. In conclusion, it seems
interruption of the explained lethal circles may convert COVID-19 to a simple common cold. The above drugs and supplements could be examined via registered clinical trials along with conventional multi drug regimen and anti-viral therapeutic guidelines.
References:

1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.
2. Chen H, Guo MS J, Wang C, Luo F, Yu X, Zhang W, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. The Lancet. 2020;395(10226):809-15.
3. de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14(8):523-34.
4. Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol. 2020;92(4):418-23.
5. Chan JF, Kok KH, Zhu Z, Chu H, To KK, Yuan S, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9(1):221-36.
6. Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet. 2020;395(10225):689-97.
7. Li X, Geng B, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. Journal of Pharmaceutical Analysis. 2020.
8. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565-74.
9. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631-7.
10. Wit ED, Doremalen NV, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14:523-34.
11. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265-9.
12. Belouzard S, Chu VC, Whittaker GR. Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. Proc Natl Acad Sci U S A. 2009;106(14):5871-6.
13. Tian X, Li C, Huang A, Xia S, Lu S, Shi Z, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerging Microbes & Infections. 2020;9(1):382-5.
14. Wevers BA, Hoek Lvd. Renin–angiotensin system in human coronavirus pathogenesis. Future Virology. 2010;5(2):145-61.
15. Millet JK, Whittaker GR. Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein. Proc Natl Acad Sci U S A. 2014;111(42):15214-9.
16. Perlman S, Netland J. Coronavirus post-SARS: update on replication and pathogenesis. Nat Rev Microbiol. 2009;7(6):439-50.
17. Fung TS, Liu DX. Human Coronavirus: Host-Pathogen Interaction. Annual review of microbiology. 2019;73:529-57.
18. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS. Journal of virology. 2020.
19. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Medicine. 2020:1-5.
20. Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Development Research. 2020.
21. Pizzino G, Irrera N, Cunicotta M, Pallio G, Mannino F, Arcoraci V, et al. Oxidative Stress: Harms and Benefits for Human Health. Oxid Med Cell Longev. 2017;2017:8416763.
22. Wu JQ, Kosten TR, Zhang XY. Free radicals, antioxidant defense systems, and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2013;46:200-6.
23. Kryston TB, Georgiev AB, Pissis P, Georgakilas AG. Role of oxidative stress and DNA damage in human carcinogenesis. Mutat Res. 2011;711(1-2):193-201.
24. Mathews MT, Berk BC. PARP-1 inhibition prevents oxidative and nitrosative stress-induced endothelial cell death via transactivation of the VEGF receptor 2. Arterioscler Thromb Vasc Biol. 2008;28(4):711-7.
25. Grunewald ME, Chen Y, Kuny C, Maejima T, Lease R, Ferraris D, et al. The coronavirus macrodomain is required to prevent PARP-mediated inhibition of virus replication and enhancement of IFN expression. PLoS pathogens. 2019;15(5):e1007756.
26. Andrabli SA, Umanah GK, Chang C, Stevens DA, Karuppagounder SS, Gagne JP, et al. Poly(ADP-ribose) polymerase-dependent energy depletion occurs through inhibition of glycolysis. Proc Natl Acad Sci U S A. 2014;111(28):10209-14.
27. Lange I, Yamamoto S, Partida-Sanchez S, Mori Y, Fleig A, Penner R. TRPM2 functions as a lysosomal Ca2+-release channel in beta cells. Sci Signal. 2009;2(71):ra23.
28. Perraud AL, Fleig A, Dunn CA, Bagley LA, Launay P, Schmitz C, et al. ADP-ribose gating of the calcium-permeable LTRPC2 channel revealed by Nudix motif homology. Nature. 2001;411(6837):595-9.
29. Ishii M, Shimizu S, Hagiwara T, Wajima T, Miyazaki A, Mori Y, et al. Extracellular-added ADP-ribose increases intracellular free Ca2+ concentration through Ca2+ release from stores, but not through TRPM2-mediated Ca2+ entry, in rat beta-cell line RIN-5F. J Pharmacol Sci. 2006;101(2):174-8.
30. Sumoza-Toledo A, Penner R. TRPM2: a multifunctional ion channel for calcium signalling. J Physiol. 2011;589(Pt 7):1515-25.
31. Boshtam M, Asgary S, Kouhpayeh S, Shariati L, Khanahmad H. Aptamers Against Pro- and Anti-Inflammatory Cytokines: A Review. Inflammation. 2017;40(1):340-9.
32. Shahbazi Dastjerdeh M, Kouhpayeh S, Sabzehei F, Khanahmad H, Salehi M, Mohammadi Z, et al. Zinc Finger Nuclease: A New Approach to Overcome Beta-Lactam Antibiotic Resistance. Jundishapur J Microbiol. 2016;9(1):e29384.
33. Shariati L, Modarressi MH, Tabatabaiefar MA, Kouhpayeh S, Hejazi Z, Shahbazi M, et al. Engineered zinc-finger nuclease to generate site-directed modification in the KLF1 gene for fetal hemoglobin induction. J Cell Biochem. 2018.
34. Chen C, Zhang XR, Ju ZY, He WF. [Advances in the research of cytokine storm mechanism induced by Corona Virus Disease 2019 and the corresponding immunotherapies]. Zhonghua shao shang za zhi = Zhonghua shaoshang zazhi = Chinese journal of burns. 2020;36(0):E005.
35. Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, et al. Coronavirus infections and immune responses. Journal of Medical Virology. 2020.
36. Shimabukuro-Vornhagen A, Godel P, Subklewe M, Stemmler HJ, Schlosser HA, Schlaak M, et al. Cytokine release syndrome. Journal for immunotherapy of cancer. 2018;6(1):56.
37. Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. Journal of Pharmaceutical Analysis. 2020.
38. Feng X, Koh DW. Roles of Poly (ADP-Ribose) Glycohydrolase in DNA Damage and Apoptosis. International Review of Cell and Molecular Biology. 2013;304.
39. Guo F, Sun YB, Su L, Li S, Liu ZF, Li J, et al. Losartan attenuates paraquat-induced pulmonary fibrosis in rats. Hum Exp Toxicol. 2015;34(5):497-505.
40. Liao JK. Linking endothelial dysfunction with endothelial cell activation. J Clin Invest. 2013;123(2):540-1.
41. Endemann DH, Schiffrin EL. Endothelial dysfunction. J Am Soc Nephrol. 2004;15(8):1983-92.
42. Pialoux V, Mounier R, Brown AD, Steinback CD, Rawling JM, Poulin MJ. Relationship between oxidative stress and HIF-1 alpha mRNA during sustained hypoxia in humans. Free Radic Biol Med. 2009;46(2):321-6.
43. McMahon S, Grondin F, McDonald PP, Richard DE, Dubois CM. Hypoxia-enhanced expression of the proprotein convertase furin is mediated by hypoxia-inducible factor-1: impact on the bioactivation of proproteins. J Biol Chem. 2005;280(8):6561-9.
44. Chen X, Touyz RM, Park JB, Schiffrin EL. Antioxidant effects of vitamins C and E are associated with altered activation of vascular NADPH oxidase and superoxide dismutase in stroke-prone SHR. Hypertension. 2001;38(3 Pt 2):606-11.
45. Annuk M, Zilmer M, Lind L, Linde T, Fellstrom B. Oxidative stress and endothelial function in chronic renal failure. J Am Soc Nephrol. 2001;12(12):2747-52.
46. Heitzer T, Schlinzig T, Krohn K, Meinerz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation. 2001;104(22):2673-8.
47. Hasdan G, Benchetrit S, Rashid G, Green J, Bernheim J, Rathaus M. Endothelial dysfunction and hypertension in 5/6 nephrectomized rats are mediated by vascular superoxide. Kidney Int. 2002;61(2):586-90.
48. Furchgott RF. The 1996 Albert Lasker Medical Research Awards. The discovery of endothelium-derived relaxing factor and its importance in the identification of nitric oxide. JAMA. 1996;276(14):1186-8.
49. Sena CM, Pereira AM, Seica R. Endothelial dysfunction - a major mediator of diabetic vascular disease. Biochim Biophys Acta. 2013;1832(12):2216-31.
50. De Caterina R, Libby P, Peng HB, Thannickal VJ, Rajavashisth TB, Gimbrone MA, Jr., et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest. 1995;96(1):60-8.
51. Zeiher AM, Fisslthealer B, Schray-Utz B, Busse R. Nitric oxide modulates the expression of monocyte chemoattractant protein 1 in cultured human endothelial cells. Circ Res. 1995;76(6):980-6.
52. Eberhardt W, Beeg T, Beck HF, Walpen S, Gauer S, Bohles H, et al. Nitric oxide modulates expression of matrix metalloproteinase-9 in rat mesangial cells. Kidney Int. 2000;57(1):59-69.
53. Uemura S, Matsushita H, Li W, Glassford AJ, Asagami T, Lee KH, et al. Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. Circ Res. 2001;88(12):1291-8.
54. Dhananjayan R, Koundinya KS, Malati T, Kutala VK. Endothelial Dysfunction in Type 2 Diabetes Mellitus. Indian J Clin Biochem. 2016;31(4):372-9.
55. Radomski MW, Palmer RM, Moncada S. The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res Commun. 1987;148(3):1482-9.
56. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci U S A. 1991;88(11):4651-5.
57. Mombouli JV, Vanhoutte PM. Endothelial dysfunction: from physiology to therapy. J Mol Cell Cardiol. 1999;31(1):61-74.
58. Verma S, Anderson TJ. Fundamentals of endothelial function for the clinical cardiologist. Circulation. 2002;105(5):546-9.
59. Xu J, Yang J, Chen J, Luo Q, Zhang Q, Zhang H. Vitamin D alleviates lipopolysaccharide-induced acute lung injury via regulation of the renin-angiotensin system. Molecular medicine reports. 2017;16(5):7432-8.

60. Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zuo W. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. BioRxiv. 2020.

61. Al-Hadad HS, Neama AK, Al-Mousawi A. Hypertension and Vitamin D Deficiency. Indian Journal of Public Health Research & Development. 2019;10(2):704-9.

62. Andersen LB, Przybyl L, Haase N, von Versen-Höynck F, Qadri F, Jørgensen JS, et al. Vitamin D Depletion Aggravates Hypertension and Target-Organ Damage. Journal of the American Heart Association. 2015;4(2):e001417.

63. Mabley JG, Wallace R, Pacher P, Murphy K, Szabo C. Inhibition of poly(adenosine diphosphate-ribose) polymerase by the active form of vitamin D. Int J Mol Med. 2007;19(6):947-52.

64. Lee HJ, Yoon YS, Lee SJ. Mechanism of neuroprotection by trehalose: controversy surrounding autophagy induction. Cell Death Dis. 2018;9(7):712.

65. Wang G, Ma H, Wang J, Khan MF. Contribution of poly(ADP-ribose)polymerase-1 activation and apoptosis in trichloroethene-mediated autoimmunity. Toxicol Appl Pharmacol. 2019;362:28-34.

66. Amarowicz R. Tannins: the new natural antioxidants? Eur J Lipid Sci Technol 2007;109(2007):549-51.

67. Ambreen M, Mirza SA. Evaluation of anti-inflammatory and wound healing potential of tannins isolated from leaf callus cultures of Achyranthes aspera and Ocimum basilicum. Pak J Pharm Sci. 2020;33(1(Supplementary)):361-9.

68. Yeo J, Lee J, Yoon S, Kim WJ. Tannic acid-based nanogel as an efficient anti-inflammatory agent. Biomater Sci. 2020;8(4):1148-59.

69. Luo X, Li M, Zhan K, Yang W, Zhang L, Wang K, et al. Selective inhibition of TRPM2 channel by two novel synthesized ADPR analogues. Chem Biol Drug Des. 2018;91(2):552-66.

70. Chi Y, Li K, Yan Q, Koizumi S, Shi L, Takahashi S, et al. Nonsteroidal anti-inflammatory drug flufenamic acid is a potent activator of AMP-activated protein kinase. J Pharmacol Exp Ther. 2011;339(1):257-66.

71. Kume S, Haneda M, Kanasaki K, Sugimoto T, Araki S, Isshiki K, et al. SIRT1 inhibits transforming growth factor beta-induced apoptosis in glomerular mesangial cells via Smad7 deacetylation. J Biol Chem. 2007;282(1):151-8.

72. Matsuoka H, Ishii M, Goto A, Sugimoto T. Role of serotonin type 2 receptors in regulation of aldosterone production. Am J Physiol. 1985;249(2 Pt 1):E234-8.

73. Cotton SA, Herrick AL, Jayson MI, Freemont AJ. TGF beta—a role in systemic sclerosis? J Pathol. 1998;184(1):4-6.

74. McKay S, de Jongste JC, Saxena PR, Sharma HS. Angiotensin II induces hypertrophy of human airway smooth muscle cells: expression of transcription factors and transforming growth factor-beta1. Am J Respir Cell Mol Biol. 1998;18(6):823-33.

75. Sanderson N, Factor V, Nagy P, Kopp J, Kondaiah P, Wakefield L, et al. Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci U S A. 1995;92(7):2572-6.
76. Stula M, Pinto YM, Gschwend S, Teisman AC, van Gilst WH, Bohm M, et al. Interaction of the renin-angiotensin system and the endothelin system in cardiac hypertrophy. J Cardiovasc Pharmacol. 1998;31 Suppl 1:S403-5.

77. Ünübol M, Yavaşoğlu I, Acar B, Kadıköylü G, Bolaman Z. The effect of losartan on platelet aggregation and hematological parameters in patients with newly diagnosed hypertension. Meandros Medical Journal. 2015;16:91-6.

78. Cardoso PRG, Matias KA, Dantas AT, Marques CDL, Pereira MC, Duarte A, et al. Losartan, but not Enalapril and Valsartan, Inhibits the Expression of IFN-gamma, IL-6, IL-17F and IL-22 in PBMCs from Rheumatoid Arthritis Patients. Open Rheumatol J. 2018;12:160-70.

79. Shen L, Mo H, Cai L, Kong T, Zheng W, Ye J, et al. Losartan prevents sepsis-induced acute lung injury and decreases activation of nuclear factor kappaB and mitogen-activated protein kinases. Shock. 2009;31(5):500-6.

80. Sun M, Yang J, Sun Y, Su G. Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia. Zhonghua jie he he hu xi za zhi= Zhonghua jiehe he huxi zazhi= Chinese journal of tuberculosis and respiratory diseases. 2020;43:E014.

81. Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM. Upregulation of angiotensin-converting enzyme 2 over myocardial infarction by blockade of angiotensin II receptors. Hypertension. 2004;43(5):970-6.

82. Furuhashi M, Moniwa N, Mita T, Fuseya T, Ishimura S, Ohno K, et al. Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker. American journal of hypertension. 2015;28(1):15-21.

83. Chen GL, Zeng B, Eastmond S, Elsenussi SE, Boa AN, Xu SZ. Pharmacological comparison of novel synthetic fenamate analogues with econazole and 2-APB on the inhibition of TRPM2 channels. Br J Pharmacol. 2012;167(6):1232-43.

84. Hill K, Benham CD, McNulty S, Randall AD. Flufenamic acid is a pH-dependent antagonist of TRPM2 channels. Neuropharmacology. 2004;47(3):450-60.

85. Kraft R, Grimm C, Frenzel H, Harteneck C. Inhibition of TRPM2 cation channels by N-(p-amylcinnamoyl)anthranilic acid. Br J Pharmacol. 2006;148(3):264-73.

86. Hill K, McNulty S, Randall AD. Inhibition of TRPM2 channels by the antifungal agents clotrimazole and econazole. Naunyn Schmiedebergs Arch Pharmacol. 2004;370(4):227-37.

87. Behrendt HJ, Germann T, Gillen C, Hatt H, Jostock R. Characterization of the mouse cold-menthol receptor TRPM8 and vanilloid receptor type-1 VR1 using a fluorometric imaging plate reader (FLIPR) assay. Br J Pharmacol. 2004;141(4):737-45.

88. Togashi K, Inada H, Tominaga M. Inhibition of the transient receptor potential cation channel TRPM2 by 2-aminoethoxydiphenyl borate (2-APB). Br J Pharmacol. 2008;153(6):1324-30.

89. Jiang H, Zeng B, Chen GL, Bot D, Eastmond S, Elsenussi SE, et al. Effect of non-steroidal anti-inflammatory drugs and new fenamate analogues on TRPC4 and TRPC5 channels. Biochem Pharmacol. 2012;83(7):923-31.
90. Kolisek M, Beck A, Fleig A, Penner R. Cyclic ADP-ribose and hydrogen peroxide synergize with ADP-ribose in the activation of TRPM2 channels. Mol Cell. 2005;18(1):61-9.

91. Moreau C, Kirchberger T, Swarbrick JM, Bartlett SJ, Fliegert R, Yorgan T, et al. Structure-activity relationship of adenosine 5'-diphosphoribose at the transient receptor potential melastatin 2 (TRPM2) channel: rational design of antagonists. J Med Chem. 2013;56(24):10079-102.

92. Olchanski N, Hansen RN, Pope E, D'Cruz B, Fergie J, Goldstein M, et al. Palivizumab Prophylaxis for Respiratory Syncytial Virus: Examining the Evidence Around Value. Open Forum Infect Dis. 2018;5(3):ofy031.
Legend

Figure 1. Four major pathways involved in the pathogenesis of nCoV 19. 1-The renin-angiotensin (RAS) signaling pathway, 2- oxidative stress and cell death, 3- cytokines storm and 4- Endothelial dysfunction.
